Effect of the Small Molecule Inhibitor of Kallikrein-Related Peptidase 7 Against Ovarian CancerA

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ovarian cancer often exhibits elevated expression of kallikrein-related peptidase 7 (KLK7).
• KLK7 plays a role in tumor progression, including proliferation, migration, and invasion.
• Targeting KLK7 presents a potential therapeutic avenue for ovarian cancer treatment.

Purpose of the Study:

• To investigate the anti-cancer effects of the small molecule inhibitor C42 on ovarian cancer.
• To assess the impact of C42 on KLK7-expressing ovarian cancer cells (SKOV3).
• To evaluate the feasibility of C42 as a novel therapeutic strategy for ovarian cancer.

Main Methods:

• In vitro studies utilized CCK-8 assay, flow cytometry, cell scratch, and Transwell assays to evaluate proliferation, migration, and invasion of SKOV3 cells treated with C42.
• Western blotting was employed to analyze protein expression changes.
• An in vivo subcutaneous xenograft model in nude mice assessed C42's effects on tumor growth and metastasis, with immunohistochemistry examining protein markers.

Main Results:

• C42 significantly suppressed the proliferation, migration, and invasion of SKOV3 ovarian cancer cells in vitro (P<0.001).
• In vivo, C42 treatment (10.2 mg/kg) reduced tumor weight (P=0.009) and liver metastases in the xenograft model.
• Immunohistochemistry showed decreased expression of Ki-67, matrix metalloproteinase-9, and Vimentin in C42-treated tumors (P<0.05).

Conclusions:

• The small molecule inhibitor C42 demonstrates significant efficacy in suppressing ovarian cancer cell proliferation, migration, and invasion.
• C42 effectively reduces tumor growth and metastasis in a preclinical ovarian cancer model.
• These findings support the potential of C42 as a targeted therapeutic agent for KLK7-overexpressing ovarian cancer.